Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Publication | Closed Access

DOI

278

Citations

References

2007

Year

John B. Buse, David C. Klonoff, Loretta L. Nielsen, Xuesong Guan, Christopher L. Bowlus, John H. Holcombe, David Maggs, Matthew Wintle

Clinical Therapeutics

ObesityMetabolic SyndromeInterim AnalysisDiabetes ManagementBody CompositionMedicineDiabetesType 2Exenatide TreatmentDiabetes MellitusPharmacologyMetabolic HealthHealth Sciences